Background. In studies of hepatitis C virus (HCV) seroconversion in injection drug users (IDUs), some have questioned whether underreporting of syringe sharing, a stigmatized behavior, has led to misattribution of HCV risk to other injection-related behaviors.
out the world [2] [3] [4] . Extremely high prevalence rates of HCV infection have been reported in IDUs, up to 98% in China and 85%-95% in many other regions [5] [6] [7] . HCV infection incidence rates in the range of 10-40 cases/100 person-years [8] [9] [10] exceed human immunodeficiency virus (HIV) incidence rates in IDUs by a substantial margin and illustrate the hyperendemic nature of HCV infection in this population [6] .
It is well established that parenteral exposure to infectious blood is a highly efficient means of transmitting HCV [4] . Illicit drug injection practices may include the shared use of syringes and drug preparation equipment, such as drug cookers, filtration cotton and rinse water; each of these behaviors may conceivably result in parenteral exposure to infectious blood [11] . Significant declines in the prevalence of syringe sharing have been reported in many regions, parallel with the expansion of HIV education and syringe availability programs [12] . A recent meta-analysis demonstrated a lengthening in time to HCV infection among IDUs in industrialized countries [13] , suggesting that declines in injection risk behavior have reduced transmission. However, the shared use of other drug preparation materials remains relatively common even in IDU populations where syringe sharing is relatively uncommon [14] . The environmental stability of HCV remains an open question, because there is no reliable cell culture system to assess the viability of HCV [15] . HCV in dried plasma left at room temperature for periods of у16 h but р4 days has been shown to cause infection in experimental animals [16] . This has clear implications for HCV transmission via exposure to drug preparation materials that may be intermittently reused and shared among injectors.
A number of cohort studies have examined drug injection practices as risk factors for HCV seroconversion in IDUs [2, 10, [17] [18] [19] [20] . Several of these studies found associations between HCV transmission and the shared use of drug preparation equipment [2, 10, 17, 18, 20] including a study showing genetically related strains of HCV in individuals who shared only drug cookers and cotton [21] . Concern has been raised whether these are spurious associations caused by underreporting of syringe sharing, a stigmatized behavior [22] . This could occur if HCV seroconverters who share drug preparation equipment fail to report syringe sharing. Each of the previous seroconversion studies used interviewer-administered questionnaires to collect behavioral data; more participants report socially undesirable behavior with computer-assisted self-interviewing (CASI) methods of survey administration than with interviewer-administered questionnaires [23, 24] . In our multisite study of young IDUs-recruited in Baltimore, Maryland; Chicago, Illinois; Los Angeles, California; New York, New York; and Seattle, Washington-we examined the relationship between HCV seroconversion and injection risk behaviors measured with audio CASI. Thus, one source of measurement error (social desirability bias) was likely lessened, strengthening inference with respect to the contribution of drug preparation equipment sharing to HCV seroconversion.
METHODS
Participants were sought for enrollment in a randomized controlled trial of a behavioral intervention to reduce risk of HIV and HCV infection, the Drug User Intervention Trial (DUIT) [25] . Recruitment for this study took place between May 2002 and January 2004. Street outreach, advertising, and couponbased participant referrals were used to recruit young active injectors. To be eligible, individuals were required to have injected an illicit drug in the past 6 months, reside in the recruitment city with no plans to move within 12 months, and be English-speaking, aged 15-30 years, and seronegative for HIV and HCV antibody. A baseline screening visit included a behavioral assessment interview followed by HIV and HCV antibody testing. Individuals who tested negative for both infections were invited to enroll in the trial. Those who agreed were randomly assigned to either the intervention arm (the DUIT Peer Education Intervention), or an attention-control arm [25] . Each arm consisted of six 2-h sessions conducted during a 3-week period. Informed consent was obtained from participants, and human experimentation guidelines from the US Department of Health and Human Services, the Centers for Disease Control and Prevention, and all collaborating institutions were followed.
At baseline, 3-and 6-month follow-up visits, participants completed behavioral risk surveys via audio CASI. Audio CASI was used to address low literacy among IDUs by adding audio recordings of each question, which respondents could listen to on headphones while viewing the questions on a computer screen. The survey asked about injection with a syringe used by another IDU and the shared use of drug cookers, filtration cotton, or water used to rinse a syringe. Questions were also asked about dividing drugs between у2 injectors with a syringe ("backloading").
At each visit, venipuncture was performed, and a specimen was tested for HIV and HCV antibody. HIV antibody testing employed standard enzyme-linked immunosorbent assay and Western blot methods. Baseline specimens were tested for HCV antibody with a second-or third-generation enzyme immunoassay (second generation, Abbott Laboratories; third generation, Ortho Diagnostic Systems). Reactive samples were retested in duplicate with enzyme immunoassays and were considered positive if reactive at у1 of the repeat tests. To determine HCV seroconversion at follow-up visits, specimens were tested using the baseline testing algorithm, and repeatedly reactive samples were confirmed using second-and third-generation recombinant immunoblot assays (RIBA-2.0 [Abbott Laboratories] and RIBA-3.0 [Ortho Diagnostic Systems], respectively). The date of seroconversion was estimated by using the midpoint between the date of the negative HCV test at the baseline assessment and the date of the first positive HCV test result. Person-time for incidence rate calculations for participants who did not seroconvert was defined as the difference between the date of the negative HCV test at the baseline assessment and the date of the last negative HCV test. Persontime for incidence rate calculations for participants who seroconverted was estimated by using the midpoint between the date of the negative HCV test at the baseline assessment and the date of the first positive HCV test.
The interview window for 3-month follow-up visits closed 45 days after the scheduled visit; no closing date was applied to 6-month visits to allow for maximal follow-up. This analysis of HCV seroconversion included eligible subjects who enrolled in the trial and completed follow-up study visits within 12 months of the baseline. Data analysis was also restricted to subjects who reported injecting during the follow-up period, because we were not interested in examining HCV seroconversion associated with behavior unrelated to drug injection. Because HCV seroconversion was tested only at fixed followup assessments, data on seroconversion time were intervalcensored. To account for interval-and right-censoring, the SAS procedure LIFEREG (version 9.1) was used to model seroconversion. The LIFEREG procedure estimates model parameters by maximum likelihood using a Newton-Raphson algorithm [26] . Parameter estimates were converted to hazard ratios (HRs) for presentation. The unadjusted HRs in Table 1 were calculated for the samples used in multivariate models, without missing data, using procedures to account for censoring; this was done to facilitate comparison with the adjusted HRs (AHRs) in Table 2 . Thus, the HRs in Table 1 may not be consistent with the ratios of incidence rates in that table. For associations with HCV seroconversion shown to be statistically significant after adjustment for confounding, a population attributable risk percent measure was calculated using this formula: of exposure in the se-(AHR Ϫ 1)/(AHR) ϫ prevalence roconverters [27] .
Recruitment site and other contextual characteristics believed to be potentially related to risk behaviors, such as living with parents versus living alone, were evaluated as potential risk factors for HCV seroconversion. Risk behavior questions were designed to assess the 3-month period preceding each followup assessment. Risk behaviors were coded dichotomously based on whether the behavior was endorsed in either follow-up assessment. To determine the selection of variables in final models, a manual change-in-estimate backward-elimination procedure was used [28] . Initial models included variables that were associated with seroconversion in bivariate analyses (P ! ). The principal objective of this analysis was to estimate .20 the association between HCV seroconversion and the shared use of drug preparation materials (drug cookers, filtration cotton, and rinse water), as measured by audio CASI. Injection with a syringe previously used by another injector was included in the models as a likely important exposure variable.
RESULTS
There were 3285 individuals who completed the baseline study visit; 2062 were eligible to enroll in the trial. Eight hundred fifty-four (41%) enrolled in the study and were randomized. Of these, 712 (83%) completed у1 follow-up visit, and 510 reported injecting during the follow-up period. Follow-up data for 483 participants who were assessed within 12 months after completing the baseline assessment were available for analysis. Fifty-five HCV seroconversions were observed among these 483 participants, who contributed a total of 320 person-years of observation time, resulting in an overall incidence rate of 17. Table 1 shows subject characteristics for the sample and in relation to HCV seroconversion. The median age for the sample was 24 years; 66% of subjects were male; 65% were white, 18% were Hispanic, and 6% were black. At study enrollment, 42% of subjects lived with their parents, and 41% reported being homeless in the previous 6 months. Most had not completed high school, 12% were in school, and only 29% were employed in a legal occupation. The majority had been in jail or prison. Nearly half had been in a drug treatment program during the previous 3 months.
The highest incidence of HCV seroconversion was observed in Baltimore (47 cases per 100 person-years); the lowest rates were seen in Chicago (7 cases per 100 person-years) and Seattle (10 cases per 100 person-years). This incidence was also higher in those aged !24 years than in other age groups. Blacks had the lowest HCV seroconversion rates, but racial/ethnic differences were not statistically significant. Seroconversion rates were somewhat higher among subjects who had been injecting drugs р3 years.
During the 3-month period before study enrollment, approximately half of the participants reported that they were injecting every day; daily injection during follow-up was associated with an increased risk of HCV seroconversion. Injection with a syringe previously used by another injector during the follow-up period was reported by 39% of participants. Fiftyfour percent reported the shared use of drug cookers, 43% reported sharing filtration cotton, and 46% reported shared use of rinse water during the follow-up period. In univariate analysis, shared use of cotton or rinse water and backloading during the follow-up were associated with HCV seroconversion; there was a trend toward an association with syringe sharing (P p ). Overlap among indicator variables representing shared use .09 of drug preparation equipment (drug cookers, filtration cottons, and rinse water) was high, ranging from a low of 86% (of the 206 participants who shared filtration cottons, 177 also shared rinse water) to a high of 96% (of the 206 participants who shared filtration cottons, 198 also shared drug cookers). Preliminary analyses showed evidence of multicollinearity among equipment-sharing indicators. There was insufficient variance among shared use of drug preparation equipment indicators to assess their independent effects in multivariable analyses. Therefore, a summary indicator variable was created to represent the shared use of any of drug preparation equipment. As shown in Table 1 , shared use of drug preparation equipment was associated with HCV seroconversion (HR, 2.72; 95% CI, 1.09-14.09).
Modeling identified several baseline characteristics and risk behaviors that significantly predicted seroconversion. To compare the independent effects of these variables and the independent effects of the shared use of drug preparation materials variables of interest, 8 models are presented in Table 2 . All models in Table 2 control for enrollment site, living with parents at baseline, being enrolled in school, being enrolled in a drug treatment program in the 3 months before baseline, onset of injection within the previous 3 years, and an indicator for whether the participants injected every day on average during the follow-up period.
The first 6 models in Table 2 show the association between each of the injection-related risk behaviors and HCV seroconversion. Injection with a syringe previously used by another injector showed a trend toward statistical significance (model 1) (AHR, 1.82; 95% CI, 0.97-7.94). In separate models (2-4) shared use of drug cooker (AHR, 2.76; 95% CI, 1.13-20.73), filtration cotton (AHR, 2.83, 1.16-20.91), and rinse water (AHR, 2.68; 95% CI, 1.14-18.58) were all significantly associated with HCV seroconversion. Backloading was also significantly associated with seroconversion (model 5) (AHR, 2.67; 95% CI, 1.13-18.61).
The shared use of drug preparation equipment was significantly associated with HCV seroconversion (model 6), and the association remained significant after adjustment for syringe sharing and backloading (models 7 and 8). In the final model, the AHR for shared drug preparation equipment was 2.66 (95% CI, 1.03-23.92), and syringe sharing and backloading were no longer statistically significant risk factors for HCV seroconversion. Using the formula for calculating the population-attributable risk percentage [27] , we estimated that 37% of HCV seroconversions in IDUs were attributable to the shared use of drug preparation equipment.
DISCUSSION
In this multisite study, nearly 40% of HCV infections were attributable to the shared use of equipment used to prepare drugs for injection, including drug cookers, filtration cotton, and rinse water. For study subjects who reported the shared use of these materials, the risk of HCV seroconversion increased ∼3-fold. The magnitude of the association was similar to those reported in other studies that did not use audio CASI, where odds ratios ranged between 2.0 and 5.9. [2, 10, [17] [18] [19] . Our findings suggest that previously reported associations were not attributable to underascertainment of syringe sharing and misattribution of risk to other exposures. The lack of an association with syringe sharing in our study and others [10] may be explained by participants' deliberate selection of low-risk syringesharing partners. In an analysis of syringe sharing in the DUIT study by Bailey et al [29] , those who primarily injected with their sex partners were twice as likely to share syringes as those who mainly injected with other IDUs. Further post hoc analysis showed that about half of the participants sharing syringes did so with their sex partners (data not shown).
The correlation among injection risk behaviors present in this sample, which was similar to that reported in previous studies [2, 21] , precluded assessment of the independent contribution of individual exposures (cooker vs cotton vs rinse water). However, the fact that these practices rarely occur in isolation suggests that this limitation may be of little importance in developing recommendations to prevent HCV transmission. Teaching IDUs broader principles of infection control may do more to reduce exposure to HCV and other pathogens than explaining the ranking of individual behaviors in relation to the strength of their association with HCV seroconversion. A recent synthesis of qualitative research concluded that such rankings may not be particularly salient to drug users' perspectives on HCV risk [30] .
Our study findings may have been limited by the fact that injection risk behaviors differ by region in the United States [31] , and thus, a multisite study may not be ideal for calculating summary measures of risk associated with specific practices. There may also have been some residual underreporting of syringe sharing and other behaviors in this study. However, assuming that audio CASI improved measurement of stigmatized behaviors, the fact that the HRs estimated here were consistent with those reported elsewhere further strengthens inferences regarding the contribution of drug preparation equipment sharing to HCV transmission. Moreover, the proportion of participants reporting, at baseline, syringe sharing (49%), cooker sharing (67%), and cotton sharing (56%) is substantially higher than that reported in other studies of young IDUs that did not use audio CASI; in those studies in San Francisco and Montreal, 27%-29% of subjects reported syringe sharing, 14% shared cottons, and 30% shared cookers [9, 10] . This suggests that audio CASI did indeed improve measurement of behaviors associated with HCV transmission. A further strength of our analysis of the effect of equipment sharing is that we controlled for all the significant predictors, including syringe sharing and backloading.
Attributable risk measures estimate the reduction in disease that could occur if the risk factor in question were eliminated [27] . The calculation of the proportion of HCV infections in IDU that may be attributable to the shared use of drug preparation equipment (37%) depended on the strength of the association (AHR, 2.66) and the prevalence of the risk factor in those who acquire HCV infection (59%). Thus, elimination of the shared use of cookers, cottons, and rinse water would probably lead to a very substantial reduction in the occurrence of HCV infection.
The question remains how to apply these findings and those of other studies in the design of effective strategies to prevent HCV infection among drug injectors. Participants in this study were enrolled in a trial of an intervention specifically intended to reduce HIV and HCV transmission. Previous analysis of these data showed that those enrolled in the intervention arm did indeed reduce injection risk behavior, but the incidence of HCV infection was still 17 cases per 100 person-years and similar in both arms [32] . Very substantial reductions in exposure to sources of contaminated blood appear necessary to affect HCV infection rates. To avoid HCV infection, IDUs need methods to control a host of factors that interfere with safe injection, such as drug withdrawal avoidance, peer pressure to share drug injection equipment, and a chaotic drug injection setting [33, 34] . Interventions that support IDUs in their efforts to manage a highly complex set of challenges may lead to further gains in HCV control in this population. 
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